Abstract:BACKGROUND Serum amyloid A (SAA) is an acute phase protein mainly synthesized by the liver. SAA induces inflammatory phenotype and promotes cell proliferation in activated hepatic stellate cells, the major scar forming cells in the liver. However, few studies have reported on the serum levels of SAA in human liver disease and its clinical significance in various liver diseases. AIM To investigate the serum levels of SAA in patients with different liver diseases and analyze the factors associated with the alteration of SAA levels in chronic hepatitis B (CHB) patients. METHODS Two hundred and seventy-eight patients with different liver diseases and 117 healthy controls were included in this study. The patients included 205 with CHB, 22 with active autoimmune liver disease (AILD), 21 with nonalcoholic steatohepatitis (NASH), 14 with drug-induced liver injury (DILI), and 16 with pyogenic liver abscess. Serum levels of SAA and other clinical parameters were collected for the analysis of the factors associated with SAA level. Mann-Whitney U test was used to compare the serum SAA levels of patients with various liver diseases with those of healthy controls. Bonferroni test was applied for post hoc comparisons to control the probability of type 1 error (alpha = 0.05/6 = 0.008). For statistical tests of other variables, P < 0.05 was considered statistically significant. Statistically significant factors determined by single factor analysis were further analyzed by binary multivariate logistic regression analysis. RESULTS All patients with active liver diseases had higher serum SAA levels than healthy controls and the inactive CHB patients, with the highest SAA level found in patients with pyogenic liver abscess (398.4 +/- 246.8 mg/L). Patients with active AILD (19.73 +/- 24.81 mg/L) or DILI (8.036 +/- 5.685 mg/L) showed higher SAA levels than those with active CHB (6.621 +/- 6.776 mg/L) and NASH (6.624 +/- 4.891 mg/L). Single (P < 0.001) and multivariate logistic regression analyses (P = 0.039) for the CHB patients suggested that patients with active CHB were associated with an SAA serum level higher than 6.4 mg/L. Serum levels of SAA and CRP (C-reactive protein) were positively correlated in patients with CHB (P < 0.001), pyogenic liver abscess (P = 0.045), and active AILD (P = 0.02). Serum levels of SAA (0.80-871.0 mg/L) had a broader fluctuation range than CRP (0.30-271.3 mg/L). CONCLUSION Serum level of SAA is a sensitive biomarker for inflammatory activity of pyogenic liver abscess. It may also be a weak marker reflecting milder inflammatory status in the liver of patients with CHB and other active liver diseases.

High-Density Lipoproteins and Serum Amyloid A (SAA)

Implications for Central Nervous System Disease

Acute phase reactant serum amyloid A in inflammation and other diseases.

Emerging Functions of Serum Amyloid A in Inflammation

Structural studies of a serum amyloid A octamer that is primed to scaffold lipid nanodiscs

Serum amyloid A levels in patients with liver diseases.

Expression of Mouse Acute-Phase (saa1.1) and Constitutive (saa4) Serum Amyloid A Isotypes - Influence on Lipoprotein Profiles

Serum amyloid A1: Structure, function and gene polymorphism

Study on the expression of serum amyloid protein A in vivo in patients with rheumatoid arthritis

High-Density Lipoprotein (HDL) Counter-Regulates Serum Amyloid A (Saa)-Induced Spla2-Iie and Spla2-V Expression in Macrophages

Clinical significance of serum amyloid A protein in patients with chronic hepatitis C virus infection

Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1

Serum Amyloid A Activates Peroxisome Proliferator-Activated Receptor Γ Through Extracellularly Regulated Kinase 1/2 and COX-2 Expression in Hepatocytes.

Serum amyloid protein A in inflammatory bowel disease: from bench to bedside

Apolipoprotein Serum Amyloid A in Alzheimer's Disease.

Correlations between serum amyloid A protein and C‐reactive protein in infectious diseases

Serum Amyloid A Directly Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice

Serum amyloid A in uremic HDL promotes inflammation

The Association of Serum Amyloid A,coronary Heart Disease and the Risk Factors of Coronary Heart Disease

Serum Amyloid A-Mediated Inflammasome Activation of Microglial Cells in Cerebral Ischemia.